-
Featured
Brain Infusion of Genetically Modified Poliovirus Is Used to Treat Glioblastoma
A phase II trial kicked off at Massachusetts General Hospital involving multiple departments and research institutes are utilizing oncolytic viruses to treat glioblastomas.
-
Featured
Combined Blockade of ATR and PARP Effective Against Glioblastoma in Mice
The combination of olaparib and an ATR inhibitor was effective against glioblastoma in mice, providing a much-needed therapeutic breakthrough for this deadly disease.
-
Featured
Adding an NAMPT Inhibitor to Temozolomide Might Boost Its Effect in IDH-Mutant Glioma
IDH1/2-mutant glioma is often treated with temozolomide, but most of these cancers recur. Research at Massachusetts General Hospital suggests that combining the drug with an NAMPT inhibitor may improve its anticancer effect.
-
Body Composition Influences Risk of Survival After Surgery for Spinal Metastases
Elie Massaad, MD, MMSc, John H. Shin, MD, and colleagues found that body composition analysis of routinely obtained presurgical CT scans, performed by an unsupervised machine learning–based system, was superior to measurement of sarcopenia alone for predicting mortality after surgery for spinal metastases.
-
Cell-free DNA and Single-Cell RNA Analysis Useful for Studying Treatment of Leptomeningeal Disease
Priscilla K. Brastianos, MD, director of the Brain Metastasis Program at the Massachusetts General Hospital Cancer Center, and colleagues have identified cellular and molecular features that associate with response to immune checkpoint inhibitors in patients with leptomeningeal disease.
-
Cell-Free DNA Analysis Outperforms Cytology for Diagnosing Leptomeningeal Disease
Michael D. White, MD, Priscilla K. Brastianos, MD, and colleagues at the Massachusetts General Hospital Cancer Center show cell-free DNA derived from cerebrospinal fluid is more accurate and sensitive for diagnosing leptomeningeal disease than the cytologic assessment of cerebrospinal fluid.
Mass General Cancer Center Contributors
-
Bakhos A. Tannous, PhD
Associate Neuroscientist, Massachusetts General Hospital, Director, Vector Production and Development Core, Associate Professor, Harvard Medical School
Recent Article
Noninvasive Techniques in Brain Tumor Treatment -
Bob S. Carter, MD, PhD
Chief, Neurosurgery Service
Recent Article
The Future of Neurosurgery and Neuroscience at Mass General: Q&A With Bob S. Carter, MD, PhD
-
Daniel P. Cahill, MD, PhD
Neurosurgeon, Massachusetts General Hospital, Neurosurgical Oncologist, Mass General Cancer Center
Recent Article
Palbociclib Demonstrates Activity Against Progressive Brain Metastases Harboring CDK Pathway Alterations
-
Shannon Stott, PhD
Assistant Professor of Medicine, Department of Medicine, Harvard Medical School, Assistant in Genetics, Massachusetts General Hospital
Recent Article
How Liquid Biopsies Can Improve Brain Tumor Diagnoses
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology, Massachusetts General Hospital, Adeline Rose Wydotis Professor of Neurosurgery, Harvard Medical School
Recent Article
Designing Leading-Edge Immunotherapy for Brain Cancer
Stephen E. and Catherine Pappas Center for Neuro-Oncology at Mass General
The Stephen E. and Catherine Pappas Center for Neuro-Oncology offers the most advanced care for patients with brain tumors and nervous system tumors.
